Drug Profile
mRNA 1653
Alternative Names: hMPV/PIV3 vaccine - Moderna Therapeutics; mRNA-1653Latest Information Update: 09 Feb 2024
Price :
$50
*
At a glance
- Originator Moderna Therapeutics
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Metapneumovirus infections; Parainfluenza virus infections
Most Recent Events
- 11 Oct 2023 Immunogenicity and adverse event data from a phase I trial in Parainfluenza virus infections and Metapneumovirus infection presented at the IDWeek-2023 (IDW-2023)
- 15 Feb 2023 mRNA 1653 is still in phase I trial for Metapneumovirus infections (In children, In adolescents, In adults, In infants, Prevention) in USA (Parenteral) (NCT04144348)
- 15 Feb 2023 mRNA 1653 is still in phase I trial for Parainfluenza virus infections (In adolescents, In children, In infants, Prevention, In adults) in USA (Parenteral) (NCT04144348)